Display options
Cite
Mu ZZ, Zhang X, Lin YS. Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer. Chonnam Med J. 2019;55(3):127-135doi: 10.4068/cmj.2019.55.3.127.
Mu, Z. Z., Zhang, X., & Lin, Y. S. (2019). Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer. Chonnam medical journal, 55(3), 127-135. https://doi.org/10.4068/cmj.2019.55.3.127
Mu, Zhuan-Zhuan, et al. "Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer." Chonnam medical journal vol. 55,3 (2019): 127-135. doi: https://doi.org/10.4068/cmj.2019.55.3.127
Mu ZZ, Zhang X, Lin YS. Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer. Chonnam Med J. 2019 Sep;55(3):127-135. doi: 10.4068/cmj.2019.55.3.127. Epub 2019 Sep 24. PMID: 31598469; PMCID: PMC6769251.
Copy Download .nbib Format: NLM
Share it on

Chonnam Med J. 2019 Sep;55(3):127-135. doi: 10.4068/cmj.2019.55.3.127. Epub 2019 Sep 24.

Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer.

Chonnam medical journal

Zhuan-Zhuan Mu, Xin Zhang, Yan-Song Lin

Affiliations

  1. Department of Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, Beijing, China.
  2. Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China.

PMID: 31598469 PMCID: PMC6769251 DOI: 10.4068/cmj.2019.55.3.127

Abstract

Most differentiated thyroid cancer (DTC) patients have an excellent prognosis. However, about one-third of DTC patients with recurrent or metastatic disease lose the hallmark of specific iodine uptake initially or gradually and acquire radioactive iodine-refractory DTC (RAIR-DTC) with poor prognosis. Due to the potentially severe complications from unnecessarily repeated RAI therapy and encouraging progress of multiple targeted drugs for advanced RAIR-DTC patients, it has become crucial to identify RAIR-DTC early. In this review, we focus on the progress and controversies regarding the defining of RAIR-DTC, further with subsistent approaches and promising molecular nuclear medicine imaging in identifying RAIR-DTC, which may shed light on the proper management methodsof such patients.

© Chonnam Medical Journal, 2019.

Keywords: Iodine Radioisotopes; Molecular Imaging; Thyroid Neoplasms

Conflict of interest statement

CONFLICT OF INTEREST STATEMENT: None declared.

References

  1. J Clin Endocrinol Metab. 2014 Jun;99(6):E1130-6 - PubMed
  2. Cancer. 2007 Oct 1;110(7):1451-6 - PubMed
  3. J Nucl Med. 2011 May;52(5):683-9 - PubMed
  4. Eur J Nucl Med Mol Imaging. 2015 Sep;42(10):1622-3 - PubMed
  5. Lancet Diabetes Endocrinol. 2014 May;2(5):356-8 - PubMed
  6. Nucl Med Commun. 2009 Aug;30(8):639-50 - PubMed
  7. J Clin Endocrinol Metab. 2006 Feb;91(2):498-505 - PubMed
  8. Thyroid. 2010 Jan;20(1):15-23 - PubMed
  9. J Nucl Med. 1994 Feb;35(2):257-62 - PubMed
  10. J Nucl Med. 1996 Mar;37(3):446-51 - PubMed
  11. J Nucl Med. 1996 Sep;37(9):1468-72 - PubMed
  12. Br Med Bull. 1952;8(2-3):154-7 - PubMed
  13. Cancer Res. 2011 Apr 1;71(7):2417-22 - PubMed
  14. Endocr Rev. 2007 Dec;28(7):742-62 - PubMed
  15. J Nucl Med. 2017 Feb;58(2):258-265 - PubMed
  16. J Nucl Med. 2005 Jan;46 Suppl 1:107S-14S - PubMed
  17. Nat Rev Cancer. 2013 Mar;13(3):184-99 - PubMed
  18. J Clin Endocrinol Metab. 1986 Oct;63(4):960-7 - PubMed
  19. J Clin Endocrinol Metab. 2002 Apr;87(4):1521-6 - PubMed
  20. J Nucl Med. 2016 Sep;57(9):1339-42 - PubMed
  21. Ann Nucl Med. 2011 Jul;25(6):439-46 - PubMed
  22. Clin Nucl Med. 2015 Jun;40(6):469-75 - PubMed
  23. Thyroid. 2016 Dec;26(12):1712-1718 - PubMed
  24. Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):197-209 - PubMed
  25. Endocr Relat Cancer. 2014 Jan 30;21(2):161-73 - PubMed
  26. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1995-2001 - PubMed
  27. Clin Nucl Med. 2018 Aug;43(8):e265-e268 - PubMed
  28. J Clin Endocrinol Metab. 2002 Apr;87(4):1490-8 - PubMed
  29. Endocr Pract. 2014 Mar;20(3):263-75 - PubMed
  30. Nucl Med Commun. 2016 Sep;37(9):935-8 - PubMed
  31. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1354-62 - PubMed
  32. Clin Nucl Med. 2009 Jun;34(6):339-42 - PubMed
  33. J Nucl Med. 1998 Sep;39(9):1542-6 - PubMed
  34. Thyroid. 2012 Sep;22(9):884-9 - PubMed
  35. Clin Nucl Med. 2011 Feb;36(2):91-5 - PubMed
  36. Endocrine. 2019 Jan;63(1):79-86 - PubMed
  37. Eur J Nucl Med Mol Imaging. 2015 May;42(6):987-8 - PubMed
  38. J Nucl Med. 2016 May;57(5):701-7 - PubMed
  39. J Clin Oncol. 2015 Feb 20;33(6):667-8 - PubMed
  40. J Clin Oncol. 2014 Sep 1;32(25):2683-4 - PubMed
  41. Clin Nucl Med. 2017 Jan;42(1):20-25 - PubMed
  42. Clin Nucl Med. 2013 May;38(5):326-31 - PubMed
  43. Cancer Res. 1999 Jul 1;59(13):3192-8 - PubMed
  44. Surg Oncol. 2018 Dec;27(4):702-708 - PubMed
  45. J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9 - PubMed
  46. Br J Cancer. 2003 Nov 3;89(9):1638-44 - PubMed
  47. Nucl Med Commun. 2013 Sep;34(9):900-8 - PubMed
  48. Sci Rep. 2018 Jan 11;8(1):473 - PubMed
  49. Thyroid. 2012 Sep;22(9):877-83 - PubMed
  50. Endocr Relat Cancer. 2005 Jun;12(2):245-62 - PubMed
  51. J Clin Endocrinol Metab. 2006 Aug;91(8):2892-9 - PubMed
  52. Cancer Res. 2009 Nov 1;69(21):8317-25 - PubMed
  53. Clin Nucl Med. 2014 Aug;39(8):675-9 - PubMed
  54. Clin Endocrinol (Oxf). 2005 Jul;63(1):87-93 - PubMed
  55. JAMA. 2013 Apr 10;309(14):1493-501 - PubMed
  56. Eur J Endocrinol. 2018 Sep;179(3):143-151 - PubMed
  57. Thyroid. 2010 May;20(5):505-11 - PubMed
  58. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1461-2 - PubMed
  59. Thyroid. 2017 May;27(5):651-660 - PubMed
  60. Nucl Med Rev Cent East Eur. 2014;17(2):87-93 - PubMed
  61. Endocrinol Nutr. 2016 Apr;63(4):e17-24 - PubMed
  62. Thyroid Res. 2009 Jan 27;2(1):1 - PubMed
  63. Clin Nucl Med. 2018 Sep;43(9):641-647 - PubMed
  64. PLoS One. 2017 Jul 13;12(7):e0179664 - PubMed
  65. Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1144-51 - PubMed
  66. J Biol Chem. 2004 Jan 30;279(5):3439-46 - PubMed
  67. Clin Nucl Med. 2017 Jun;42(6):471-472 - PubMed
  68. Thyroid. 2016 Jan;26(1):1-133 - PubMed
  69. J Clin Oncol. 2015 Jan 1;33(1):42-50 - PubMed
  70. Clin Nucl Med. 2016 Jan;41(1):e32-8 - PubMed
  71. Eur J Nucl Med Mol Imaging. 2008 May;35(5):958-65 - PubMed
  72. J Clin Oncol. 2014 Sep 1;32(25):2718-26 - PubMed
  73. J Nucl Med. 2012 Dec;53(12):1872-7 - PubMed
  74. Nucl Med Mol Imaging. 2010 Dec;44(4):273-81 - PubMed
  75. Expert Rev Anticancer Ther. 2012 Sep;12(9):1137-47 - PubMed
  76. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed
  77. Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):950-7 - PubMed
  78. Clin Nucl Med. 2015 Aug;40(8):e417-9 - PubMed
  79. Horm Metab Res. 2010 Apr;42(4):237-40 - PubMed
  80. Thyroid. 2019 Apr;29(4):461-470 - PubMed
  81. Clin Nucl Med. 2015 Feb;40(2):111-5 - PubMed
  82. Eur J Endocrinol. 2015 Sep;173(3):399-408 - PubMed
  83. Endocr Relat Cancer. 2015 Jun;22(3):419-29 - PubMed
  84. J Nucl Med. 2016 Jan;57(1):103-8 - PubMed
  85. Ann Oncol. 2001;12 Suppl 2:S41-5 - PubMed
  86. Thyroid. 2011 Jul;21(7):707-16 - PubMed
  87. Sci Rep. 2018 Mar 12;8(1):4352 - PubMed

Publication Types